Mixed depression and anxiety: Serotonin(1A) receptors as a common pharmacologic link

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 8, 1997, Pages 20-26

  Stahl, Stephen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; CLINICAL PRACTICE; CONFERENCE PAPER; DEPRESSION; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; SEROTONIN RELEASE; SYNDROME DELINEATION; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS;

EID: 0030788565     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychiatry 1993;54:(suppl 1):33-38
2. Stahl SM. Phenomenology of anxiety disorders: clinical heterogeneity and comorbidity. In: Westenberg HGM, Murphy DL, Den Boer JA, eds. Advances in the Neurobiology of Anxiety Disorders. Chichester, England: J Wiley & Sons. In press
3. Brown TA, O'Leary TA, Barlow DH. Generalized anxiety disorder. In: Barlow DH, ed. Clinical Handbook of Psychological Disorders. 2nd ed. New York, NY: Guilford Press; 1993:137-188
4. Barlow DH, Blanchard EB, Vermilyea JA, et al. Generalized anxiety and generalized anxiety disorder: description and reconceptualization. Am J Psychiatry 1986;143:40-44
5. Downing RW, Rickels K. Mixed anxiety-depression: fact or myth? Arch Gen Psychiatry I974;30:312-317
6. Stahl SM. Essential Psychopharmacology. New York, NY: Cambridge University Press; 1996
7. Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 1990;10(suppl 3): 101S-110S
8. Boulenger J-P, Lavallee Y-J. Mixed anxiety and depression: diagnostic issues. J Clin Psychiatry 1993;54(suppl 1):3-8
9. Wittchen H-U, Essau CA. Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J Clin Psychiatry 1993;54 (suppl 1):9-15
10. Brown TA, Barlow DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992;60:835-844
11. H. Sanderson WC, Barlow DH. A description of patients diagnosed with DSM-III-R generalized anxiety disorder. J Nerv Ment Dis 1990;178: 588-591
12. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993;150:600-607
13. Keller MB. Long term course of generalized anxiety. Neuropsychopharmacology 1994;10:134S
14. Hirschfeld RMA. Epidemiology and clinical presentation of generalized anxiety disorder in the United States. Neuropsychopharmacology 1994;10: 132S
15. Noyes R, Clancy J, Hoenck PR, et al. The prognosis of anxiety disorders. Arch Gen Psychiatry 1980;37:173-178
16. Krieg JC, Bronisch T, Wittchen H-U, et al. Anxiety disorders: a long term prospective and retrospective follow-up study of former inpatients suffering from an anxiety neurosis or phobia. Acta Psychiatr Scand 1987;76: 36-47
17. Woodruff RH, Guze SB, Clayton PJ. Anxiety neurosis among psychiatric outpatients. Compr Psychiatry 1972;13:165-170
18. Wells KB, Stewart A, Hays RD, et al. The functioning and mental well-being of depressed patients: results from the medical outcomes study. JAMA 1989;262:914-919
19. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Arch Gen Psychiatry 1993;50:85-94
20. Barrett JE, Barrett JA, Oxman TE, et al. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988;45: 1100-1106
21. Lepine J-P. Anxiety disorders in primary care. Neuropsychopharmacology 1994;10:133S
22. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990;12:355-362
23. Ormel J, Van Den Brink W, Koeter MWJ, et al. Recognition, management and outcome of psychological disorders in primary care: a naturalistic follow-up study. Psychol Med 1990;20:909-923
24. Von Korff M, Shapiro S, Burke JD, et al. Anxiety and depression in a primary care clinic. Arch Gen Psychiatry 1987;44:152-156
25. Robins LN, Regier DA. Psychiatric Disorders in America. New York, NY: The Free Press; 1991
26. Stahl SM. Targeting serotonin receptor subtypes as a strategy for the discovery of novel treatments in psychiatry. Int Rev Psychiatry 1995;7:3-4
27. 1A receptors selectively. Int Rev Psychiatry 1995;7:5-16
28. Preskorn SH. Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? Int Rev Psychiatry 1995;7:17-28
29. Stahl SM, Frakes DC. Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. Int Rev Psychiatry 1995;7:29-40
30. Keppel-Hesselink JM, Sambunaris A. Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int Rev Psychiatry 1995;7:41-54
31. Kunovac JL, Stahl SM. Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int Rev Psychiatry 1995;7:55-68
32. Leonard BE. Biological markers of serotonin receptors in depression and animal models of depression. Int Rev Psychiatry 1995;7:69-84
33. Rausch JL, LaFrance C, Stahl SM. Serotonin receptor-specific mediation of antidepressant treatment effects in depressed patients. Int Rev Psychiatry 1995;7:85-98
34. 2 receptor subtypes in human brain. Int Rev Psychiatry 1995;7:99-104
35. 1A receptor selective agents in anxiety disorders: the developmental situation in Japan. Int Rev Psychiatry 1995; 7:105-114
36. Swerdlow NR. Serotonin, obsessive compulsive disorder and the basal ganglia. Int Rev Psychiatry 1995;7:115-130
37. Paniccia GS, Rapaport MH. Serotonin receptors, social phobia and panic disorder. Int Rev Psychiatry 1995;7:131-140
38. Rickels K, Schweizer E. Treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993;54:(suppl 1):20-23
39. Wittchen H-U. Differences between the US and European view of the diagnosis of anxiety. Neuropsychopharmacology 1994;10:131S
40. 1A agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10:67S-76S
41. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting depressive symptoms. J Clin Psychiatry 1996;57:287-291
42. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987;1:470-480
43. 1A receptor agonists on 5-HT release in rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 1993;348:339-346
44. 1 receptor agonists and p-chloroamphetamine. Synapse 1990;5:120-133
45. Godbout R, Chaput Y, Blier P, et al. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine-I: effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology 1991;30:679-690
46. 1A agonist 8-OH-DPAT preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 1988;343:463-471
47. 1A agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci 1991;48:1779-1786
48. Hutson PH, Sarna GS, O'Connell MT, et al. Hippocampal 5-HT synthesis and release in vivo are decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis. Neurosci Lett 1989;100:276-280
49. Johansson CE, Meyerson BJ. The effects of long term treatment with 8-OH-DPAT on the lordosis response and hypothermia in female rats. Eur J Pharmacol 1991;196:143-147
50. Johansson CE, Myerson BJ, Hoglund AU. The long term effects of 8-OH-DPAT on copulatory and exploratory behaviour in male rats. Eur J Pharmacol 1990;178:1-4
51. 1A autoreceptors by chronic administration of 8-OH-DPAT. Neuropharmacology 1992;31:1073-1076
52. 1A receptor agonist 8-OH-DPAT. Neuropharmacology 1990;29:85-91
53. Schechter LE, Bolanos FJ, Gozlan H, et al. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther 1990;255:1335-1347
54. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 1989;96:283-290
55. Sharp T, Bramwell SR, Grahame-Smith DG. Effect of acute and repeated administration of buspirone on the release of 5-HT in rat hippocampus in vivo as detected by microdialysis. Fund Clin Pharmacol 1991;5:434
56. Adell A, Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-HT in raphe nuclei and frontal cortex: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 1991; 343:237-244
57. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-HT in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992; 229:101-103
58. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15: 243-245
59. Blier P, De Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatment: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7(suppl 6):24S-35S
60. Chaput Y, De Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986;333:342-348
61. Chaput Y, De Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiological study in the rat. Neuropsychopharmacol 1991;5:219-229
62. De Montigny C, Pineyro G, Chaput Y, et al. Electrophysiological studies on the effects of long term reuptake inhibition of the function of 5-HT neurons. Clin Neuropharmacol 1992;15 (suppl 1A):440A-441A
63. Fuller R. Minireview: uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994;55:163-167
64. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 1992;584:322-324